HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol

Inclusion Criteria Concurrent Medication: Allowed: * Oral trimethoprim/sulfamethoxazole. * Aerosolized pentamidine. * Dapsone. * Fluconazole. * Ketoconazole. * Itraconazole. * Rifabutin. * Filgrastim (G-CSF). * Antiretroviral agents. Patients must have: * AIDS by CDC criteria. * CMV retinitis as determined by a SOCA-certified ophthalmologist, with lesion size, location, and severity as specified in the Disease Status field. Prior Medication: Allowed: * Prophylaxis with anti-CMV agents. Exclusion Criteria Concurrent Medication: Excluded: * Ongoing therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents with anti-CMV activity. * Therapy with nephrotoxic drugs, including amphotericin B, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine. Patients with the following prior conditions are excluded: * History of renal disease or renal dialysis. * History of clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. * History of clinically significant probenecid allergy. Prior Medication: Excluded: * Prior therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents with anti-CMV activity. * Therapy with nephrotoxic drugs within the past 7 days, including amphotericin B, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine. Drug or alcohol abuse sufficient to hinder compliance with study.